FDA Warning Letters and Health Canada Alerts as a Vendor Check

How does a research buyer search the FDA warning-letter database and Health Canada's advisories for a prospective vendor, and what does a letter establish and not establish about that vendor?

A search of the FDA warning-letter database takes a few minutes and costs nothing. It tells you whether the agency has written to a company, when, from which office, and for what stated reason. A search of Health Canada's recalls and advisories site does the same for Canadian notices. Together they are an independent check on a vendor, one the vendor does not control.

What the check can establish is narrow. A letter is evidence that the agency formed a view about a company's conduct on a given date. It is not a court finding, and the absence of a letter is not a clean bill of health. This article explains how to run the search, how to read what comes back, and where the check stops.

What a warning letter is in FDA's enforcement ladder

A warning letter sits part-way up an enforcement ladder. Below it are inspectional observations and untitled letters. Above it are seizures, injunctions and prosecutions. FDA describes a warning letter as an advisory notice that gives the company an opportunity to correct a violation voluntarily before the agency considers further action, and it does not issue one in every case.

That framing explains both the value and the limit. The value is that the agency has put its view in writing and made it public. The limit is that the letter records an allegation of non-compliance at a point in time. The company may then have corrected the matter, disputed it or done neither, and the letter alone does not tell you which.

Searching the FDA database

FDA publishes warning letters in a searchable table ^[1]. As the page stood on 10 October 2026, it offered a search box, a filter for the issuing office, filters for letter issue date and posted date, a year filter, and a filter for letters that have a response or a close-out letter attached. The results list shows the posted date, the issue date, the company name, the issuing office, the subject, whether response and close-out letters exist, and an excerpt. The table can be downloaded as a spreadsheet.

There is no separate subject filter on that page, so the subject has to be read from the results column. The page also does not say which fields the search box covers, so test it. Search the company's trading name, its legal name, the domain name and any former names you have seen. Run each separately, because a letter is filed under the name FDA used when it wrote.

1. Search the exact legal name from the invoice or registry record, then the trading name, then the web domain.
2. Narrow by year, or by posted date, to see recent letters first.
3. Open each hit and read the letter in full rather than the excerpt.
4. Note the issuing office. Letters on drugs and labeling usually come from the drug centre; other offices write about devices, food or manufacturing practice.
5. Check whether a response or a close-out letter is linked, and read it too.

FDA also keeps a separate health fraud product database ^[2]. It is a different resource with a different scope, so check its page for what it lists and search it as well.

Reading a letter

A letter has a recognisable structure. It names the company and the address, says when and how the agency reviewed the company's operations or website, lists the conduct it cites, states the legal provisions it relies on, and sets a deadline, commonly fifteen working days, to respond in writing with the steps taken. It ends by noting that the letter does not necessarily list every violation.

Read four things. The legal basis tells you what kind of problem the agency saw. The conduct cited tells you what it relied on. The deadline tells you whether the company was expected to respond, and the response and close-out links tell you what happened next. The database page itself adds a caution: matters described in a letter may have been the subject of later interaction between the agency and the recipient that changed their regulatory status.

The 2026 letters to online peptide sellers

In 2026 FDA issued warning letters to online sellers of peptide products. Secondary reporting describes one group of letters dated 31 March 2026, sent to seven firms, five running websites and two running online marketplace stores ^[5]. Another group is dated 24 August 2026 and went to four firms after FDA reviewed their websites in July ^[4]. Both accounts say the letters came from the drug centre. This summary relies on those secondary accounts. The letters themselves are in the database and should be read from there.

The reporting describes the legal basis in two provisions of the Federal Food, Drug, and Cosmetic Act: the definition of a drug by its intended effect on the body, and the prohibition on introducing unapproved new drugs into interstate commerce ^[4][5]. In both groups, the accounts say FDA looked at objective evidence of what a seller intended, such as the claims on its pages and the supplies and online tools it presented alongside the products, rather than at a disclaimer or a label alone.

For a buyer, the useful point is about method. The agency reads a vendor's whole website. A vendor whose pages go beyond describing laboratory materials draws that attention, and the plain-language background on what a research-chemical vendor is allowed to say explains the line. This article does not repeat the content the letters quote, and you do not need it to run the check.

Health Canada advisories and the recalls database

The Government of Canada runs a single recalls and safety alerts site that covers food, consumer products, health products and vehicles ^[3]. It has a keyword search, paginated listings, email and feed subscriptions, and downloadable open data. When the page was read on 10 October 2026, it did not show a separate category for notices about unauthorized health products, and the search results should not be assumed to include every notice Health Canada has published.

Search by company name, by domain and by product terms, and note the dates. Health Canada also publishes advisories on its own pages, so a vendor-specific search of the Health Canada site as a whole, in addition to the recalls site, is a reasonable second pass.

What a letter establishes, and what it does not

Two further limits are worth stating. The check is geographic. FDA writes about conduct within its jurisdiction, so a vendor selling from abroad may never receive a letter and may still be an unsuitable supplier. And it is lagging: a letter follows a review, and a review follows months of activity.

Adding the check to the due-diligence file

Treat the search as a dated record. In the vendor file, write the date of the search, the databases used, the names and domains searched, and the outcome, including a null outcome. Save a copy of any letter found, with the response and close-out if present.

Repeat it on a schedule. Once a year is a reasonable interval for a supplier you use regularly, and again whenever a vendor's conduct changes, for example after a change of name or a new website. The file then shows what you knew and when you checked, which is what a reviewer or an auditor will ask.